Nicotinamide Mononucleotide: The efficacy and safety of supplementation in healthy middle‑aged adults
Nicotinamide Mononucleotide Research
In humans, enzymes use nicotinamide mononucleotide (NNM) to generate nicotinamide adenine dinucleotide (NAD), a coenzyme central to metabolism and energy production. As we age, NMN levels naturally decline as such, research into NMN has been undertaken in recent years into its potential to help increase lifespan and health span.
As well as being central to metabolism and energy production, NMN is associated with DNA repair, gene expression and cellular stress responses. Click here to read a review on NMN published in 2020.
Recent research
Research published in GeroScience in December 2022, Yi, et al. share their finding from a group of 80 healthy middle-aged adults given β‑nicotinamide mononucleotide (NMN) for 60 days.
Doses of NMN were either 300 mg, 600 mg or 900mg. The primary objective was to evaluate blood nicotinamide adenine dinucleotide (NAD) concentration. The second objective was to evaluate the safety and tolerability of NMN supplementation via physical assessment using a six-minute walk test.
NAD blood levels were significantly elevated compared to baseline in all three groups at 30 days and 60 days, with no increase observed in a group taking a placebo over the same periods.
Groups given NMN significantly increased the distance covered in the six-minute walk test, with the groups receiving 600 mg and 900 mg significantly increasing their distance covered at 30 and 60 days compared to baseline. And the group given 300 mg significantly increased their distance at 60 days.
All groups given NMN increased their distance at 30 and 60 days compared to the placebo group, where no significant change was found compared to baseline.
No significant differences were found between the groups given 900 mg and 600 mg, suggesting no additional benefits of supplementing at levels above 600 mg.
Please read the paper below for further information about Yi, et al. and their findings.